Target General Infomation
Target ID
T14597 (Former ID: TTDS00249)
Target Name
Erbb2 tyrosine kinase receptor (HER2)
Synonyms
p185erbB2; Tyrosine kinase-type cell surface receptor HER2; Receptor tyrosine-protein kinase erbB-2; Proto-oncogene c-ErbB-2; Proto-oncogene Neu; NGL; NEU; Metastatic lymph node gene 19 protein; MLN19; MLN 19; HER2; CD340
Gene Name
ERBB2
Target Type
Successful target
[1]
Disease [+] 3 Target-related Diseases +
1 Breast cancer [ICD-11: 2C60-2C6Y]
2 Lung cancer [ICD-11: 2C25]
3 Prostate cancer [ICD-11: 2C82]
Function
Protein tyrosine kinase that is part of several cell surface receptor complexes, but that apparently needs a coreceptor for ligand binding. Essential component of a neuregulin-receptor complex, although neuregulins do not interact with it alone. GP30 is a potential ligand for this receptor. Regulates outgrowth and stabilization of peripheral microtubules (MTs). Upon ERBB2 activation, the MEMO1-RHOA-DIAPH1 signaling pathway elicits the phosphorylation and thus the inhibition of GSK3B at cell membrane. This prevents the phosphorylation of APC and CLASP2, allowing its association with the cell membrane. In turn, membrane-bound APC allows the localization of MACF1 to the cell membrane, which is required for microtubule capture and stabilization.
BioChemical Class
Kinase
UniProt ID
ERBB2_HUMAN
EC Number
EC 2.7.10.1
Sequence
MELAALCRWGLLLALLPPGAASTQVCTGTDMKLRLPASPETHLDMLRHLYQGCQVVQGNL
ELTYLPTNASLSFLQDIQEVQGYVLIAHNQVRQVPLQRLRIVRGTQLFEDNYALAVLDNG
DPLNNTTPVTGASPGGLRELQLRSLTEILKGGVLIQRNPQLCYQDTILWKDIFHKNNQLA
LTLIDTNRSRACHPCSPMCKGSRCWGESSEDCQSLTRTVCAGGCARCKGPLPTDCCHEQC
AAGCTGPKHSDCLACLHFNHSGICELHCPALVTYNTDTFESMPNPEGRYTFGASCVTACP
YNYLSTDVGSCTLVCPLHNQEVTAEDGTQRCEKCSKPCARVCYGLGMEHLREVRAVTSAN
IQEFAGCKKIFGSLAFLPESFDGDPASNTAPLQPEQLQVFETLEEITGYLYISAWPDSLP
DLSVFQNLQVIRGRILHNGAYSLTLQGLGISWLGLRSLRELGSGLALIHHNTHLCFVHTV
PWDQLFRNPHQALLHTANRPEDECVGEGLACHQLCARGHCWGPGPTQCVNCSQFLRGQEC
VEECRVLQGLPREYVNARHCLPCHPECQPQNGSVTCFGPEADQCVACAHYKDPPFCVARC
PSGVKPDLSYMPIWKFPDEEGACQPCPINCTHSCVDLDDKGCPAEQRASPLTSIISAVVG
ILLVVVLGVVFGILIKRRQQKIRKYTMRRLLQETELVEPLTPSGAMPNQAQMRILKETEL
RKVKVLGSGAFGTVYKGIWIPDGENVKIPVAIKVLRENTSPKANKEILDEAYVMAGVGSP
YVSRLLGICLTSTVQLVTQLMPYGCLLDHVRENRGRLGSQDLLNWCMQIAKGMSYLEDVR
LVHRDLAARNVLVKSPNHVKITDFGLARLLDIDETEYHADGGKVPIKWMALESILRRRFT
HQSDVWSYGVTVWELMTFGAKPYDGIPAREIPDLLEKGERLPQPPICTIDVYMIMVKCWM
IDSECRPRFRELVSEFSRMARDPQRFVVIQNEDLGPASPLDSTFYRSLLEDDDMGDLVDA
EEYLVPQQGFFCPDPAPGAGGMVHHRHRSSSTRSGGGDLTLGLEPSEEEAPRSPLAPSEG
AGSDVFDGDLGMGAAKGLQSLPTHDPSPLQRYSEDPTVPLPSETDGYVAPLTCSPQPEYV
NQPDVRPQPPSPREGPLPAARPAGATLERPKTLSPGKNGVVKDVFAFGGAVENPEYLTPQ
GGAAPQPHPPPAFSPAFDNLYYWDQDPPERGAPPSTFKGTPTAENPEYLGLDVPV
Drugs and Modes of Action
Approved Drug(s) [+] 7 Approved Drugs +
1 BIBW 2992 Drug Info Approved Non-small-cell lung cancer [2], [3]
2 Dacomitinib Drug Info Approved Non-small-cell lung cancer [4]
3 Lapatinib Drug Info Approved Breast cancer [5], [6]
4 Masoprocol Drug Info Approved Prostate cancer [7], [8]
5 NERATINIB MALEATE Drug Info Approved HER2/NEU overexpressing breast cancer [10]
6 Pertuzumab Drug Info Approved Breast cancer [11], [12]
7 Trastuzumab Drug Info Approved Breast cancer [8], [13], [14]
Clinical Trial Drug(s) [+] 52 Clinical Trial Drugs +
1 Merimepodib Drug Info Approved Breast cancer [9]
2 Bevacizumab + Trastuzumab Drug Info Phase 3 Breast cancer [15]
3 HKI-272 Drug Info Phase 3 Breast cancer [16], [17]
4 Margetuximab Drug Info Phase 3 Breast cancer [17], [18]
5 Nelipepimut S Drug Info Phase 3 Non-hodgkin lymphoma [19]
6 NeuVax Drug Info Phase 3 Breast cancer [19]
7 PF-05280014 Drug Info Phase 3 Breast cancer [20]
8 Taxol/Paraplatin/Herceptin Drug Info Phase 3 Breast cancer [21]
9 Trastuzumab-DM1 Drug Info Phase 3 Breast cancer [22]
10 Varlitinib Drug Info Phase 2/3 Metastatic biliary tract neoplasms [17]
11 Anti-CD3 and anti-Her2/neu bispecific antibody-armed activated T cells Drug Info Phase 2 Breast cancer [23]
12 AZD8931 Drug Info Phase 2 Breast cancer [24], [25]
13 BMS-599626 Drug Info Phase 2 Solid tumour/cancer [26], [27]
14 CI-1033 Drug Info Phase 2 Lymphoma [28], [29]
15 CP-724714 Drug Info Phase 2 Lymphoma [30], [31]
16 DN24-02 Drug Info Phase 2 Urogenital cancer [32]
17 Ertumaxomab Drug Info Phase 2 Breast cancer [33], [34]
18 HER-2 Protein AutoVac Drug Info Phase 2 Breast cancer [35]
19 Her2-targeted autologous T-cell therapy Drug Info Phase 2 Glioblastoma multiforme [36]
20 HER2/neu peptide vaccine Drug Info Phase 2 Breast cancer [37]
21 HM-78136B Drug Info Phase 2 Solid tumour/cancer [38], [39]
22 MCLA-128 Drug Info Phase 2 Breast cancer [17]
23 MGAH22 Drug Info Phase 2 Solid tumour/cancer [40]
24 MM-111 Drug Info Phase 2 Gastric adenocarcinoma [41]
25 Pazopanib + Tyverb/Tykerb Drug Info Phase 2 Inflammatory breast cancer [42]
26 ABY-025 Drug Info Phase 1/2 Bladder cancer [43]
27 AGN-208397 Drug Info Phase 1/2 Retina venous occlusion [44]
28 Anti-HER2 CAR-T Drug Info Phase 1/2 Colorectal cancer [45]
29 AU105 Drug Info Phase 1/2 Recurrent glioblastoma [17], [18], [46]
30 AVX901 Drug Info Phase 1/2 Breast cancer [18], [47], [48]
31 CART-HER-2 Drug Info Phase 1/2 Solid tumour/cancer [49]
32 HER-2-targeting CAR T Cells Drug Info Phase 1/2 Breast cancer [50]
33 Sym013 Drug Info Phase 1/2 Epithelial ovarian cancer [17]
34 S-222611 Drug Info Phase 1b Malignant solid tumour [51]
35 ARRY-380 Drug Info Phase 1 Solid tumour/cancer [52]
36 CAR-T cells targeting HER2 Drug Info Phase 1 Solid tumour/cancer [53]
37 CAR-T Cells targeting HER2 Drug Info Phase 1 Pancreatic cancer [54]
38 Cipatinib Drug Info Phase 1 Solid tumour/cancer [55]
39 CUDC-101 Drug Info Phase 1 Solid tumour/cancer [56]
40 HER2-CAR T Cells Drug Info Phase 1 Malignant neoplasm [57]
41 HER2-specific CAR T cell Drug Info Phase 1 Atypical teratoid/rhabdoid tumour [58]
42 HER2-specific T cells Drug Info Phase 1 Recurrent glioblastoma [59]
43 HER2p63-71 peptide vaccine Drug Info Phase 1 Solid tumour/cancer [60]
44 JNJ-26483327 Drug Info Phase 1 Solid tumour/cancer [61]
45 MEDI4276 Drug Info Phase 1 Solid tumour/cancer [17], [18]
46 MM-302 Drug Info Phase 1 Breast cancer [62]
47 MVA HER-2 AutoVac Drug Info Phase 1 Breast cancer [63]
48 Recombinant human Erbb3 fragment therapeutic tumor vaccine Drug Info Phase 1 Solid tumour/cancer [64]
49 TAK-285 Drug Info Phase 1 Solid tumour/cancer [65]
50 TrasGEX Drug Info Phase 1 Solid tumour/cancer [66]
51 VM-206 Drug Info Phase 1 Solid tumour/cancer [67]
52 Zemab Drug Info Phase 1 Solid tumour/cancer [68]
Discontinued Drug(s) [+] 3 Discontinued Drugs +
1 Her-2-Bi-armed ATC Drug Info Discontinued in Phase 2 Breast cancer [69]
2 TAK165 Drug Info Discontinued in Phase 1 Solid tumour/cancer [70], [71]
3 GW-974 Drug Info Terminated Breast cancer [72]
Preclinical Drug(s) [+] 1 Preclinical Drugs +
1 Trastuzumab biosimilar Drug Info Application submitted Breast cancer [18]
Mode of Action [+] 7 Modes of Action +
Inhibitor [+] 25 Inhibitor drugs +
1 BIBW 2992 Drug Info [73]
2 Lapatinib Drug Info [75], [76]
3 Pertuzumab Drug Info [78], [79]
4 HKI-272 Drug Info [82]
5 Nelipepimut S Drug Info [84]
6 Taxol/Paraplatin/Herceptin Drug Info [86]
7 Merimepodib Drug Info [90]
8 AZD8931 Drug Info [92], [93]
9 BMS-599626 Drug Info [82]
10 CI-1033 Drug Info [82]
11 CP-724714 Drug Info [82]
12 HER-2 Protein AutoVac Drug Info [35]
13 Her2-targeted autologous T-cell therapy Drug Info [95]
14 HM-78136B Drug Info [97]
15 Pazopanib + Tyverb/Tykerb Drug Info [90]
16 AGN-208397 Drug Info [101]
17 AVX901 Drug Info [47]
18 Sym013 Drug Info [17]
19 S-222611 Drug Info [51]
20 JNJ-26483327 Drug Info [103]
21 TAK-285 Drug Info [107]
22 TAK165 Drug Info [82]
23 GW-974 Drug Info [112]
24 (1-Benzyl-1H-indazol-5-yl)-quinazolin-4-yl-amine Drug Info [113]
25 (1-Benzyl-1H-indol-5-yl)-quinazolin-4-yl-amine Drug Info [113]
Antagonist [+] 5 Antagonist drugs +
1 Dacomitinib Drug Info [74]
2 NERATINIB MALEATE Drug Info [10]
3 PF-05280014 Drug Info [85]
4 MCLA-128 Drug Info [17]
5 Trastuzumab biosimilar Drug Info [18]
Modulator [+] 11 Modulator drugs +
1 Masoprocol Drug Info [77]
2 Varlitinib Drug Info [89]
3 DN24-02 Drug Info [94]
4 MGAH22 Drug Info [98]
5 MM-111 Drug Info [99]
6 ARRY-380 Drug Info [102]
7 Cipatinib Drug Info [89]
8 CUDC-101 Drug Info [56]
9 MEDI4276 Drug Info [17]
10 MM-302 Drug Info [104]
11 PF 5208766 Drug Info [114]
Enhancer [+] 1 Enhancer drugs +
1 ABY-025 Drug Info [100]
CAR-T-Cell-Therapy [+] 8 CAR-T-Cell-Therapy drugs +
1 Anti-HER2 CAR-T Drug Info [45]
2 CART-HER-2 Drug Info [49]
3 HER-2-targeting CAR T Cells Drug Info [50]
4 CAR-T cells targeting HER2 Drug Info [53]
5 CAR-T Cells targeting HER2 Drug Info [54]
6 HER2-CAR T Cells Drug Info [57]
7 HER2-specific CAR T cell Drug Info [58]
8 HER2-specific T cells Drug Info [59]
Immunomodulator [+] 1 Immunomodulator drugs +
1 AU105 Drug Info [18]
Binder [+] 1 Binder drugs +
1 TA1-RTA Drug Info [116]
Target Regulators
Target-regulating microRNAs
Target-regulating Transcription Factors
Target-interacting Proteins
Target Profiles in Patients
Target Expression
 Profile (TEP)
Drug Resistance
 Mutation (DRM)
Target Affiliated Biological Pathways
KEGG Pathway [+] 14 KEGG Pathways +
1 ErbB signaling pathway
2 Calcium signaling pathway
3 HIF-1 signaling pathway
4 Focal adhesion
5 Adherens junction
6 Pathways in cancer
7 Proteoglycans in cancer
8 MicroRNAs in cancer
9 Pancreatic cancer
10 Endometrial cancer
11 Prostate cancer
12 Bladder cancer
13 Non-small cell lung cancer
14 Central carbon metabolism in cancer
NetPath Pathway [+] 1 NetPath Pathways +
1 TCR Signaling Pathway
Panther Pathway [+] 2 Panther Pathways +
1 Cadherin signaling pathway
2 EGF receptor signaling pathway
Pathwhiz Pathway [+] 1 Pathwhiz Pathways +
1 Phosphatidylinositol Phosphate Metabolism
PID Pathway [+] 5 PID Pathways +
1 ErbB4 signaling events
2 ErbB2/ErbB3 signaling events
3 ErbB receptor signaling network
4 a6b1 and a6b4 Integrin signaling
5 Validated targets of C-MYC transcriptional repression
Reactome [+] 8 Reactome Pathways +
1 SHC1 events in ERBB2 signaling
2 PLCG1 events in ERBB2 signaling
3 PIP3 activates AKT signaling
4 GRB2 events in ERBB2 signaling
5 PI3K events in ERBB2 signaling
6 Constitutive Signaling by Aberrant PI3K in Cancer
7 Sema4D induced cell migration and growth-cone collapse
8 RAF/MAP kinase cascade
WikiPathways [+] 12 WikiPathways +
1 DNA Damage Response (only ATM dependent)
2 ErbB Signaling Pathway
3 EGF/EGFR Signaling Pathway
4 Focal Adhesion
5 Extracellular vesicle-mediated signaling in recipient cells
6 Bladder Cancer
7 Signaling by ERBB2
8 Integrated Pancreatic Cancer Pathway
9 Signaling Pathways in Glioblastoma
10 Leptin signaling pathway
11 miR-targeted genes in muscle cell - TarBase
12 Semaphorin interactions
Target-Related Models and Studies
Target Validation
References
REF 1 Her2/neu is not a commonly expressed therapeutic target in melanoma -- a large cohort tissue microarray study. Melanoma Res. 2004 Jun;14(3):207-10.
REF 2 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 5667).
REF 3 BIBW-2992, a dual receptor tyrosine kinase inhibitor for the treatment of solid tumors. Curr Opin Investig Drugs. 2008 Dec;9(12):1336-46.
REF 4 2018 FDA drug approvals.Nat Rev Drug Discov. 2019 Feb;18(2):85-89.
REF 5 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 5692).
REF 6 FDA Approved Drug Products from FDA Official Website. 2009. Application Number: (NDA) 022059.
REF 7 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 4265).
REF 8 Natural products as sources of new drugs over the last 25 years. J Nat Prod. 2007 Mar;70(3):461-77.
REF 9 FDA Approved Drug Products from FDA Official Website. 2009. Application Number: (NDA) 022059.
REF 10 2017 FDA drug approvals.Nat Rev Drug Discov. 2018 Feb;17(2):81-85.
REF 11 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 5046).
REF 12 Pertuzumab, trastuzumab, and docetaxel for HER2-positive metastatic breast cancer (CLEOPATRA study): overall survival results from a randomised, double-blind, placebo-controlled, phase 3 study. Lancet Oncol. 2013 May;14(6):461-71.
REF 13 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 5082).
REF 14 Radium 223 dichloride for prostate cancer treatment. Drug Des Devel Ther. 2017 Sep 6;11:2643-2651.
REF 15 AVEREL: a randomized phase III Trial evaluating bevacizumab in combination with docetaxel and trastuzumab as first-line therapy for HER2-positive locally recurrent/metastatic breast cancer. J Clin Oncol. 2013 May 10;31(14):1719-25.
REF 16 Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800021154)
REF 17 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
REF 18 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
REF 19 ClinicalTrials.gov (NCT01479244) Efficacy and Safety Study of NeuVax (Nelipepimut-S or E75) Vaccine to Prevent Breast Cancer Recurrence. U.S. National Institutes of Health.
REF 20 ClinicalTrials.gov (NCT02187744) A Study Of PF-05280014 Or Trastuzumab Plus Taxotere And Carboplatin In HER2 Positive Breast Cancer In The Neoadjuvant Setting (REFLECTIONS B327-04). U.S. National Institutes of Health.
REF 21 Randomized phase III study of trastuzumab, paclitaxel, and carboplatin compared with trastuzumab and paclitaxel in women with HER-2-overexpressing metastatic breast cancer. J Clin Oncol. 2006 Jun 20;24(18):2786-92.
REF 22 Patient-reported outcomes from EMILIA, a randomized phase 3 study of trastuzumab emtansine (T-DM1) versus capecitabine and lapatinib in human epidermal growth factor receptor 2-positive locally advanced or metastatic breast cancer. Cancer. 2014 Mar 1;120(5):642-51.
REF 23 Journal of Clinical Oncology, 2008 ASCO Annual Meeting Proceedings (Post-Meeting Edition), Vol 26, No 15S (May 20 Supplement), 2008: 3034.
REF 24 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7717).
REF 25 ClinicalTrials.gov (NCT02117167) Intergroup Trial UNICANCER UC 0105-1305/ IFCT 1301: Efficacy of Targeted Drugs Guided by Genomic Profils in Metastatic NSCLC Patients. U.S. National Institutes of Health.
REF 26 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7647).
REF 27 ClinicalTrials.gov (NCT01614522) A Clinical Trial Evaluating the Effect of ASLAN001 in Patients With Recurrent/Metastatic Gastric Cancer Whose Tumors Are Either HER-2 Amplified or Co-expressing HER-1and HER-2. U.S. National Institutes of Health.
REF 28 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 5675).
REF 29 Tyrosine kinase inhibitors. 17. Irreversible inhibitors of the epidermal growth factor receptor: 4-(phenylamino)quinazoline- and 4-(phenylamino)pyrido[3,2-d]pyrimidine-6-acrylamides bearing additional solubilizing functions. J Med Chem. 2000 Apr 6;43(7):1380-97.
REF 30 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7883).
REF 31 ClinicalTrials.gov (NCT00102895) A Research Study of CP-724,714 in Patients With HER2 Overexpressing Metastatic Breast Cancer. U.S. National Institutes of Health.
REF 32 ClinicalTrials.gov (NCT01353222) DN24-02 as Adjuvant Therapy in Subjects With High Risk HER2+ Urothelial Carcinoma. U.S. National Institutes of Health.
REF 33 Trifunctional antibody ertumaxomab: Non-immunological effects on Her2 receptor activity and downstream signaling. MAbs. 2012 Sep-Oct;4(5):614-22.
REF 34 Ertumaxomab: a trifunctional antibody for breast cancer treatment. Expert Opin Investig Drugs. 2008 Oct;17(10):1553-8.
REF 35 Treatment of HER2-positive breast cancer: current status and future perspectives. Nat Rev Clin Oncol. 2011 Nov 29;9(1):16-32.
REF 36 Adoptive cell therapies for glioblastoma. Front Oncol. 2013 Nov 11;3:275.
REF 37 ClinicalTrials.gov (NCT01729884) Vaccine Therapy in Treating Patients With Stage IV Hormone Receptor Positive Breast Cancer. U.S. National Institutes of Health.
REF 38 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7903).
REF 39 ClinicalTrials.gov (NCT02216916) Phase II Trial of HM781-36B in Patients With Metastatic/Recurrent Head and Neck Squamous Cell Carcinoma (HNSCC) After Failure of or Unfit for Platinum-containing Therapy. U.S. National Institutes of Health.
REF 40 ClinicalTrials.gov (NCT01828021) Phase 2 Study of the Monoclonal Antibody MGAH22 (Margetuximab) in Patients With Relapsed or Refractory Advanced Breast Cancer. U.S. National Institutes of Health.
REF 41 ClinicalTrials.gov (NCT01774851) A Study of MM-111 and Paclitaxel With Trastuzumab in Patients HER2 Positive Carcinomas of the Distal Esophagus, Gastroesophageal (GE) Junction and Stomach. U.S. National Institutes of Health.
REF 42 A randomized phase II study of lapatinib + pazopanib versus lapatinib in patients with HER2+ inflammatory breast cancer. Breast Cancer Res Treat. 2013 Jan;137(2):471-82.
REF 43 ClinicalTrials.gov (NCT01858116) PET Study of Breast Cancer Patients Using [68Ga]ABY-025. U.S. National Institutes of Health.
REF 44 ClinicalTrials.gov (NCT01027650) Safety and Efficacy of AGN208397 in the Treatment of Macular Edema Associated With Retinal Vein Occlusion (RVO). U.S. National Institutes of Health.
REF 45 ClinicalTrials.gov (NCT02713984) A Clinical Research of CAR T Cells Targeting HER2 Positive Cancer
REF 46 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
REF 47 ClinicalTrials.gov (NCT01526473) A Phase I Study To Evaluate The Antitumor Activity And Safety Of AVX901. U.S. National Institutes of Health.
REF 48 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
REF 49 ClinicalTrials.gov (NCT01935843) Treatment of Chemotherapy Refractory Human Epidermalgrowth Factor Receptor-2( HER-2) Positive Advanced Solid Tumors
REF 50 ClinicalTrials.gov (NCT02547961) Chimeric Antigen Receptor-Modified T Cells for Breast Cancer
REF 51 Clinical pipeline report, company report or official report of Shionogi (2011).
REF 52 ClinicalTrials.gov (NCT01921335) ARRY-380 + Trastuzuamab for Breast w/ Brain Mets. U.S. National Institutes of Health.
REF 53 ClinicalTrials.gov (NCT03198052) HER2/Mesothelin/Lewis-Y/PSCA/MUC1/PD-L1/CD80/86-CAR-T Cells Immunotherapy Against Cancers
REF 54 ClinicalTrials.gov (NCT03267173) Evaluate the Safety and Efficacy of CAR-T in the Treatment of Pancreatic Cancer.
REF 55 ClinicalTrials.gov (NCT01301911) Study of Cipatinib in Patients With HER2 Positive or Uncertain Advanced Breast Cancer. U.S. National Institutes of Health.
REF 56 A Phase I Study of CUDC-101, a Multitarget Inhibitor of HDACs, EGFR, and HER2, in Combination with Chemoradiation in Patients with Head and Neck Squamous Cell Carcinoma. Clin Cancer Res. 2015 Apr 1;21(7):1566-73.
REF 57 ClinicalTrials.gov (NCT03696030) HER2-CAR T Cells in Treating Participants With Brain or Leptomeningeal Metastases
REF 58 ClinicalTrials.gov (NCT03500991) HER2-specific CAR T Cell Locoregional Immunotherapy for HER2-positive Recurrent/Refractory Pediatric CNS Tumors
REF 59 ClinicalTrials.gov (NCT02442297) T Cells Expressing HER2-specific Chimeric Antigen Receptors(CAR) for Patients With Glioblastoma
REF 60 Development of a cancer vaccine: peptides, proteins, and DNA. Cancer Chemother Pharmacol. 2000;46 Suppl:S77-82.
REF 61 ClinicalTrials.gov (NCT00676299) A Safety and Dose-finding Study of JNJ-26483327, a Drug in Development for Cancer, for Patients With Advanced and/or Refractory Solid Malignancies.. U.S. National Institutes of Health.
REF 62 ClinicalTrials.gov (NCT01304797) Safety and Pharmacokinetic Study of MM-302 in Patients With Advanced Breast Cancer. U.S. National Institutes of Health.
REF 63 ClinicalTrials.gov (NCT01152398) A Safety and Immunology Study of a Modified Vaccinia Vaccine for HER-2(+) Breast Cancer After Adjuvant Therapy. U.S. National Institutes of Health.
REF 64 Clinical pipeline report, company report or official report of Zensun.
REF 65 ClinicalTrials.gov (NCT00535522) A Safety and Pharmacokinetic Study of TAK-285 in Patients With Advanced Cancer. U.S. National Institutes of Health.
REF 66 ClinicalTrials.gov (NCT01409343) TrasGEX Dose Escalation Study. U.S. National Institutes of Health.
REF 67 ClinicalTrials.gov (NCT01895491) Safety Study of VM206RY in Subjects With Expression of HER2 in Breast Cancer. U.S. National Institutes of Health.
REF 68 Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800026315)
REF 69 Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800028450)
REF 70 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 6011).
REF 71 Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800019257)
REF 72 Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800010108)
REF 73 Boehringer Ingelheim. Product Development Pipeline. June 2 2009.
REF 74 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7422).
REF 75 Triple negative breast cancer--current status and prospective targeted treatment based on HER1 (EGFR), TOP2A and C-MYC gene assessment. Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub. 2009 Mar;153(1):13-7.
REF 76 Multi-target therapeutics: when the whole is greater than the sum of the parts. Drug Discov Today. 2007 Jan;12(1-2):34-42.
REF 77 Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.
REF 78 Clinical pipeline report, company report or official report of Roche (2009).
REF 79 Pertuzumab. Drugs Fut 2008, 33(2): 123 ISSN 0377-8282.
REF 80 Knockouts model the 100 best-selling drugs--will they model the next 100 Nat Rev Drug Discov. 2003 Jan;2(1):38-51.
REF 81 Anti-ErbB-2 monoclonal antibodies and ErbB-2-directed vaccines. Cancer Immunol Immunother. 2002 Jan;50(11):569-87.
REF 82 A comparison of physicochemical property profiles of marketed oral drugs and orally bioavailable anti-cancer protein kinase inhibitors in clinical development. Curr Top Med Chem. 2007;7(14):1408-22.
REF 83 J Clin Oncol 31, 2013 (suppl; abstr 3004).
REF 84 The HER2 peptide nelipepimut-S (E75) vaccine (NeuVax in breast cancer patients at risk for recurrence: correlation of immunologic data with clinical response. Immunotherapy. 2014;6(5):519-31.
REF 85 Comparative nonclinical assessments of the proposed biosimilar PF-05280014 and trastuzumab (Herceptin( )). BioDrugs. 2014 Oct;28(5):451-9.
REF 86 Two concurrent phase II trials of paclitaxel/carboplatin/trastuzumab (weekly or every-3-week schedule) as first-line therapy in women with HER2-overexpressing metastatic breast cancer: NCCTG study 983252. Clin Breast Cancer. 2005 Dec;6(5):425-32.
REF 87 Clinical pipeline report, company report or official report of Genentech (2009).
REF 88 Trastuzumab--mechanism of action and use in clinical practice. N Engl J Med. 2007 Jul 5;357(1):39-51.
REF 89 Interpreting expression profiles of cancers by genome-wide survey of breadth of expression in normal tissues. Genomics 2005 Aug;86(2):127-41.
REF 90 Clinical pipeline report, company report or official report of GlaxoSmithKline (2009).
REF 91 Use of anti-CD3 x anti-HER2/neu bispecific antibody for redirecting cytotoxicity of activated T cells toward HER2/neu+ tumors. J Hematother Stem Cell Res. 2001 Apr;10(2):247-60.
REF 92 Clinical pipeline report, company report or official report of AstraZeneca (2009).
REF 93 Characterization of AZD8931, a potent reversible small molecule inhibitor against epidermal growth factor receptor (EGFR), erythroblastic leukemia viral oncogene homolog 2 (HER2) and 3 (HER3) with a unique and balanced pharmacological profile. J Clin Oncol 27:15s, 2009.
REF 94 Treatment with autologous antigen-presenting cells activated with the HER-2 based antigen Lapuleucel-T: results of a phase I study in immunologic and clinical activity in HER-2 overexpressing breast cancer. J Clin Oncol. 2007 Aug 20;25(24):3680-7.
REF 95 A new hope in immunotherapy for malignant gliomas: adoptive T cell transfer therapy. J Immunol Res. 2014;2014:326545.
REF 96 N-terminally LRMK-linked HER-2 peptides, AE-37 [p776(774-788)] and AE-47 [Ava-F7(776-788)], aid differentiation of E75-TCR+CD8+ cells to perforin-positive cells. Anticancer Res. 2009 Jul;29(7):2427-35.
REF 97 Antitumor activity of HM781-36B, a highly effective pan-HER inhibitor in erlotinib-resistant NSCLC and other EGFR-dependent cancer models. Int J Cancer. 2012 May 15;130(10):2445-54.
REF 98 Anti-tumor activity and toxicokinetics analysis of MGAH22, an anti-HER2 monoclonal antibody with enhanced Fcgamma receptor binding properties. Breast Cancer Res. 2011; 13(6): R123.
REF 99 Bispecific antibodies rise again. Nat Rev Drug Discov. 2014 Nov;13(11):799-801.
REF 100 Targeting of HER2-expressing tumors using 111In-ABY-025, a second-generation affibody molecule with a fundamentally reengineered scaffold. J Nucl Med. 2010 Jul;51(7):1131-8.
REF 101 New hope for dry AMD. Nat Rev Drug Discov. 2013 Jul;12(7):501-2.
REF 102 ARRY-380, a Potent, Small Molecule Inhibitor of ErbB2, Increases Survival in Intracranial ErbB2+ Xenograft Models in Mice
REF 103 National Cancer Institute Drug Dictionary (drug id 596693).
REF 104 Whole-body organ-level and kidney micro-dosimetric evaluations of (64)Cu-loaded HER2/ErbB2-targeted liposomal doxorubicin ((64)Cu-MM-302) in rodents and primates. EJNMMI Res. 2015 Apr 14;5:24.
REF 105 Active immunotherapy in HER2 overexpressing breast cancer: current status and future perspectives. Ann Oncol. 2013 Jul;24(7):1740-8.
REF 106 Clinical pipeline report, company report or official report of Zensun.
REF 107 Clinical pipeline report, company report or official report of Takeda (2009).
REF 108 J Clin Oncol 32:5s, 2014 (suppl; abstr 2515).
REF 109 WO patent application no. 2014,1441,21, Classification and actionability indices for lung cancer.
REF 110 Immunotoxins and Anticancer Drug Conjugate Assemblies: The Role of the Linkage between Components. Toxins (Basel) 2011 July; 3(7): 848-883.
REF 111 Cancer therapy with bispecific antibodies: Clinical experience. Curr Opin Mol Ther. 2010 June; 12(3): 340-349.
REF 112 WO patent application no. 2005,0443,02, Selective erbb2 inhibitor/anti-erbb antibody combinations in the treatment of cancer.
REF 113 Indazolylamino quinazolines and pyridopyrimidines as inhibitors of the EGFr and C-erbB-2. Bioorg Med Chem Lett. 2001 Jun 4;11(11):1401-5.
REF 114 Optimization of 6,7-disubstituted-4-(arylamino)quinoline-3-carbonitriles as orally active, irreversible inhibitors of human epidermal growth factor... J Med Chem. 2005 Feb 24;48(4):1107-31.
REF 115 A new human antitumor immunoreagent specific for ErbB2. Clin Cancer Res. 2002 Jun;8(6):1710-9.
REF 116 Synergistic interaction between anti-p185HER-2 ricin A chain immunotoxins and radionuclide conjugates for inhibiting growth of ovarian and breast cancer cells that overexpress HER-2. Clin Cancer Res.2000 Aug;6(8):3334-41.

If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Wang and Dr. Li.